Akers Announces Conference Call to Discuss Its Fourth Quarter and Full Year 2014 Earnings
March 19 2015 - 7:00AM
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the
"Company"), a medical device company focused on reducing the cost
of healthcare through faster, easier diagnostics, announces that
the Company will publish earnings for the 2014 fiscal year end on
Monday, March 23, 2015.
Akers will hold a conference call at 10:30 a.m. Eastern Time on
March 23, 2015. Akers' Co-Founder and Executive Chairman, Raymond
F. Akers, Jr. PhD, and Vice President of Finance, Gary Rauch, will
host the call and be available during the question and answer
session.
To participate in the call from within the U.S., please dial
1-888-271-8595 approximately 10 minutes prior to the scheduled
start time. International callers should dial 1-913-981-4901. The
Conference ID is 8825228. Interested parties can also listen via a
live Internet webcast, which can be found through the Company's
website at http://ir.akersbiosciences.com/events.cfm or
alternatively at
http://public.viavid.com/player/index.php?id=113661.
A replay of the call will be available from 1:30 p.m. Eastern
Time on March 23, 2015, until 11:59 p.m. Eastern Time on April 06,
2015. The number for the replay from within the U.S. is
1-877-870-5176, or 1-858-384-5517 for international callers; the
passcode for the replay is 8825228. In addition, a recording of the
call will be available via the Company's website at
http://ir.akersbiosciences.com/events.cfm.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products
can be found at
www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, as amended. Such forward-looking statements reflect
the Company's expectations about its future operating results,
performance and opportunities that involve substantial risks and
uncertainties. These statements include but are not limited to
statements regarding the intended terms of the offering, closing of
the offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Alexandra Roper
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2024 to Aug 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2023 to Aug 2024